<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661921</url>
  </required_header>
  <id_info>
    <org_study_id>20070212</org_study_id>
    <nct_id>NCT00661921</nct_id>
  </id_info>
  <brief_title>A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Mutiple Dose, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous AMG 108 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of blocking IL-1 signaling with AMG
      108 in type 2 diabetes mellitus patients on glycemic control, as measured by change in HbA1c
      from baseline to end of treatment (EOT).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Program Development discontinued
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c at week 14 (end of treatment)</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>40 mg AMG 108 Q2W</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg AMG 108 Q2W</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>75 mg AMG 108 Q2W</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMG 108</intervention_name>
    <description>IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.</description>
    <arm_group_label>150 mg AMG 108 Q2W</arm_group_label>
    <arm_group_label>40 mg AMG 108 Q2W</arm_group_label>
    <arm_group_label>75 mg AMG 108 Q2W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>AMG 108 volume matching placebo</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of T2DM ≥ 3 months at time of randomization

          -  HbA1c of 7.0 - 9.5% (inclusive) at screening

          -  ≥ 18 years of age at the time of randomization

          -  BMI ≥ 25 kg/m2 and ≤ 45 kg/m2 at screening, and, per patient self-report, following
             their regular weight maintenance or reduction diet for the management of diabetes for
             at least 4 weeks prior to randomization

          -  Fasting plasma glucose ≤ 240 mg/dL (13.3 mmol/L) at each of 2 determinations during
             screening (samples taken at least 1 day apart)

          -  No new therapy for the treatment of elevated blood pressure or dyslipidemia, use of
             any weight loss medication (over the counter or prescription), or initiation of a
             prescribed weight management or exercise program within 4 weeks before randomization

          -  Subject is able and willing to comply with the study's visit requirement

        Exclusion Criteria:

          -  History of type 1 insulin-dependent diabetes

          -  Significant signs and symptoms of uncontrolled hyperglycemia (ie, polyuria,
             polydypsia, polyphagia), in the opinion of the investigator

          -  History of significant weight gain or loss (+/- 5%) during the 4 weeks before
             randomization

          -  Triglycerides ≥ 400 mg/dL (4.5 mmol/L) and/or total cholesterol ≥340 mg/dL (8.7
             mmol/L) at screening

          -  Currently receiving or received within 60 days prior to screening any anti-diabetic
             pharmaceutical therapy (eg, insulin) other than metformin and/or sulfonylurea. If
             receiving metformin or sulfonylurea, doses must be stable for ≥ 60 days.

          -  Uncontrolled hypertension defined as diastolic pressure &gt; 95 mmHg and/or systolic &gt;
             170 mmHg during screening

          -  Hepatic function test (alanine aminotranferase (ALT), aspartate aminotransferase
             (AST), alkaline phosphatase, total bilirubin) results at screening &gt; 2 times the upper
             limit of normal for the central laboratory

          -  White blood cell count &lt; 3000 / μL, absolute neutrophil count (ANC) of &lt; 2500 / μL, or
             platelet count of &lt; 125,000 / μL at screening

          -  Any significant inflammatory, rheumatologic, or systemic autoimmune disease in the
             opinion of the investigator

          -  Evidence of active infection, recent infection, or chronic infection, requiring
             treatment with anti-infectives, hospitalization or IV antibiotics within 4 weeks prior
             to randomization

          -  Active or latent Mycobacterium tuberculosis infection as defined by known positive PPD
             or chest x-ray findings and failure to complete treatment with appropriate
             chemoprophylaxis, or exposure to a person with active tuberculosis within 6 months
             prior to randomization

          -  Existence of non-healing wounds or ulcers

          -  Known to be positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV)
             or human immunodeficiency virus (HIV)

          -  Estimated GFR (eGFR) at screening &lt; 30 mL/min as calculated via the MDRD equation
             (Modification of Diet in Renal Disease study group)

          -  Clinical evidence of current malignancy, with the following exceptions: basal or
             squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, prostate
             cancer (if stable localized disease, with life expectancy of &gt; 3 years); or receiving
             or has received chemotherapy and/or radiation therapy for treatment of a malignancy
             within 6 months prior to randomization

          -  Clinically significant cardiovascular disease (eg, heart failure of New York Heart
             Association [NYHA] class 3 or 4), hematological abnormality, asthma, or chronic
             obstructive pulmonary disease (eg, requiring oral or IV steroids), in the opinion of
             the investigator

          -  Receipt of any biologic or immunosuppressive therapy (experimental or commercial),
             including anakinra (Kineret®) or any tumor necrosis factor (TNF) blocking agents (eg,
             etanercept and infliximab), or live vaccines, within 3 months of randomization

          -  Previously received AMG 108

          -  Subject is evidently pregnant (eg, positive human chorionic gonadotropin [HCG] test),
             is breast feeding, or is of child-bearing potential and not using adequate
             contraceptive precautions, as determined by the investigator

          -  Subject currently is enrolled in or has not yet completed at least 30 days since
             ending other investigational device or drug study(s), or subject is receiving other
             investigational agent(s)

          -  Subject has any kind of condition (eg, psychiatric illness) or situation that, in the
             investigator's opinion, compromises the ability of the subject to give written
             informed consent, may put the subject at significant risk, may confound the study
             results, or may interfere significantly with the subject's participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>February 5, 2009</last_update_submitted>
  <last_update_submitted_qc>February 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>AMG 108</keyword>
  <keyword>HbA1C</keyword>
  <keyword>glucose</keyword>
  <keyword>metformin</keyword>
  <keyword>sulfonylurea</keyword>
  <keyword>IL-1 Inhibitor</keyword>
  <keyword>biologic</keyword>
  <keyword>subcutaneous injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

